血管升压药不影响实验性内毒素血症和脓毒症期间系统性炎症时的人脑临界闭合压
荷兰一家三级大学医院ICU的前瞻性先导研究,纳入40名健康男性接受实验性内毒素血症(LPS 2 ng/kg静注)及10例严重脓毒症或脓毒症休克患者。内毒素血症受试者随机接受去甲肾上腺素0.05 μg/kg/min、去氧肾上腺素0.5 μg/kg/min、血管加压素0.04 IU/min或生理盐水输注5小时(LPS前1小时开始)。LPS-安慰剂组脑临界闭合压(CrCP)从基线52.6 mmHg降至LPS后270分钟44.1 mmHg(P=0.03);去氧肾上腺素在LPS前使CrCP升高(46.9→53.8 mmHg,P=0.02),但LPS后各组CrCP下降程度相似;去甲肾上腺素或血管加压素在LPS前不影响CrCP。脓毒症患者CrCP为35.7 mmHg,低于LPS-安慰剂组。作者结论:血管升压药未能预防CrCP下降,脓毒症患者即便使用升压药仍有低脑血流和缺血风险。
要点
- LPS-安慰剂组CrCP从基线52.6 mmHg降至LPS后270分钟44.1 mmHg(P=0.03),提示内毒素血症导致脑动脉床血管阻力下降。
- 去氧肾上腺素0.5 μg/kg/min在LPS前使CrCP从46.9升至53.8 mmHg(P=0.02),但LPS后CrCP下降程度与安慰剂组相似。
- 去甲肾上腺素0.05 μg/kg/min或血管加压素0.04 IU/min在LPS前不影响CrCP,LPS后各组CrCP下降程度相似。
- 脓毒症患者CrCP为35.7 mmHg,低于LPS-安慰剂组基线至LPS后90分钟的水平(P<0.01)。
- 作者认为,脓毒症患者即便接受血管升压药治疗,仍存在低脑血流和缺血风险。
适用人群与场景
- 实验性内毒素血症部分:40名健康男性,接受静脉注射细菌脂多糖(LPS)2 ng/kg。
- 脓毒症部分:10例严重脓毒症或脓毒症休克患者,在荷兰一家三级大学医院ICU治疗。
诊断标准与关键阈值
- 脓毒症患者升压治疗目标:平均动脉压(MAP)>65 mmHg,同时追求正常血容量。
处置流程与药物剂量
- 内毒素血症受试者随机接受5小时输注:去甲肾上腺素0.05 μg/kg/min(LPS-nor组,n=10)、去氧肾上腺素0.5 μg/kg/min(LPS-phenyl组,n=10)、血管加压素0.04 IU/min(LPS-AVP组,n=10)或生理盐水(LPS-placebo组,n=10),均于静脉注射LPS 2 ng/kg前1小时开始。
- 脓毒症患者由医疗团队酌情进行液体复苏和使用血管升压药,目标为正常血容量和MAP>65 mmHg,使用去甲肾上腺素。
研究设计与关键结果
- 研究类型:前瞻性先导研究,纳入40名健康男性(实验性内毒素血症)和10例严重脓毒症或脓毒症休克患者。
- LPS-安慰剂组CrCP从基线52.6 [46.6-55.5] mmHg降至LPS后270分钟44.1 [41.2-51.3] mmHg(P=0.03)。
- 去氧肾上腺素组在LPS前CrCP从46.9 [38.8-53.4] mmHg升至53.8 [52.9-60.2] mmHg(P=0.02),但LPS后CrCP下降程度与LPS-安慰剂组相似。
- 去甲肾上腺素或血管加压素在LPS前不影响CrCP;LPS推注后CrCP下降在所有治疗组中相似。
- 脓毒症患者CrCP为35.7 [34.4-42.0] mmHg,低于LPS-安慰剂组从基线至LPS后90分钟的水平(P<0.01)。
证据类型、等级与局限
- 证据类型:前瞻性先导研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:实验性人内毒素血症导致CrCP下降,源于动脉床血管阻力丧失;血管升压药未能预防这一下降。
- 作者结论:脓毒症患者中的发现与LPS给药后受试者所见相当;脓毒症患者即便接受血管升压药治疗,仍有低脑血流和缺血风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM: The aim of this study was to investigate the effects of different vasopressors on the cerebral vasculature during experimental human endotoxemia and sepsis. We used the critical closing pressure (CrCP) as a measure of cerebral vascular tone.
METHODS: We performed a prospective pilot study, at the intensive care department (ICU) of a tertiary care university hospital in the Netherlands, in 40 healthy male subjects during experimental human endotoxemia (administration of bacterial lipopolysaccharide [LPS]) and in 10 patients with severe sepsis or septic shock.Subjects in the endotoxemia study were randomized to receive a 5 h infusion of either 0.05 μg/kg/min noradrenaline (n = 10, "LPS-nor"), 0.5 μg/kg/min phenylephrine (n = 10, "LPS-phenyl"), 0.04 IU/min vasopressin (n = 10, "LPS-AVP"), or saline (n = 10, "LPS-placebo") starting 1 h before intravenous administration of 2 ng/kg LPS. In patients with sepsis, fluid resuscitation and vasopressor use was at the discretion of the medical team, aiming at normovolemia and a mean arterial pressure (MAP) > 65 mm Hg, using noradrenaline.The mean flow velocity in the middle cerebral artery (MFVMCA) was measured by transcranial Doppler (TCD) with simultaneously recording of heart rate, arterial blood pressure, respiratory rate, and oxygen saturation. CrCP was estimated using the cerebrovascular impedance model.
RESULTS: The CrCP decreased in the LPS-placebo group from 52.6 [46.6-55.5] mm Hg at baseline to 44.1 [41.2-51.3] mm Hg at 270 min post-LPS (P = 0.03). Infusion of phenylephrine increased the CrCP in the period before LPS administration from 46.9 [38.8-53.4] to 53.8 [52.9-60.2] mm Hg (P = 0.02), but after LPS administration, a similar decrease was observed compared with the LPS-placebo group. Noradrenaline or vasopressin prior to LPS did not affect the CrCP. The decrease in CrCP after LPS bolus was similar in all treatment groups. The CrCP in the sepsis patients equaled 35.7 [34.4-42.0] mm Hg, and was lower compared with that in the LPS-placebo subjects from baseline until 90 min after LPS (P < 0.01).
CONCLUSIONS: Experimental human endotoxemia results in a decreased CrCP due to a loss of vascular resistance of the arterial bed. Vasopressors did not prevent this decrease in CrCP. Findings in patients with sepsis are comparable to those found in subjects after LPS administration.Patients with sepsis, despite treatment with vasopressors, have a risk for low cerebral blood flow and ischemia.
参考来源
- van den Brule JMD, Stolk R, Vinke EJ, et al. Vasopressors Do Not Influence Cerebral Critical Closing Pressure During Systemic Inflammation Evoked by Experimental Endotoxemia and Sepsis in Humans. Shock. 2018. PMID: 28991047. doi:10.1097/SHK.0000000000001003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。